# UnitedHealth Group (UNH – NYSE)  

**Analyst Rating:** HOLD — Solid core business offset by near-term cost pressures and uncertainty  
**Target Price:** USD 420 (12-month horizon)  
**Report Date:** 2025-05-15  

Last Close (2025-05-15): $389.0 · 52-Week Range: $389.0–$607.9 · Market Cap: $356B · Dividend (ttm): $8.40 · Shares O/S: 0.929B ([www.unitedhealthgroup.com](https://www.unitedhealthgroup.com/newsroom/2025/2025-2-24-uhg-authorizes-payment-quarterly-dividend.html#:~:text=The%20UnitedHealth%20Group%20,of%20business%20March%2010%2C%202025)) ([www.macrotrends.net](https://www.macrotrends.net/stocks/charts/UNH/unitedhealth-group/shares-outstanding#:~:text=2024%20%20,956))  
Key Valuation Multiples: FY25 P/E ~16.0×, FY24 P/E ~25.1×, Price/Sales ~0.9×, Price/Book ~3.6×.  Sector: Managed Health Care (Market Weight) · Financial Strength: High

## Analyst’s Notes  
• Q1 2025 results: Revenue $109.6B (+$9.8B YoY) ([www.unitedhealthgroup.com](https://www.unitedhealthgroup.com/newsroom/2025/2025-03-24-uhg-announces-q1-earnings-release-date.html#:~:text=,50%20Per%20Share)); GAAP EPS $6.85 (adj. $7.20) ([www.unitedhealthgroup.com](https://www.unitedhealthgroup.com/newsroom/2025/2025-03-24-uhg-announces-q1-earnings-release-date.html#:~:text=,50%20Per%20Share)).  UnitedHealthcare membership grew: +780K “consumers served” YTD ([www.unitedhealthgroup.com](https://www.unitedhealthgroup.com/newsroom/2025/2025-03-24-uhg-announces-q1-earnings-release-date.html#:~:text=,Year)) (including +545K seniors/complex needs ([ae.marketscreener.com](https://ae.marketscreener.com/quote/stock/UNITEDHEALTH-GROUP-INC-14750/news/UnitedHealth-Earnings-Release-Q1-2025-49645511/#:~:text=,expanded%20customer%20relationships%20in%20Kentucky)) and +700K self-funded commercial lives ([ae.marketscreener.com](https://ae.marketscreener.com/quote/stock/UNITEDHEALTH-GROUP-INC-14750/news/UnitedHealth-Earnings-Release-Q1-2025-49645511/#:~:text=,company%27s%20offerings%20for%20seniors%20and))).  Medicare Advantage membership reached 8.2M at Q1-end (≈+5% YoY) ([www.healthcaredive.com](https://www.healthcaredive.com/news/unitedhealth-unh-cuts-2025-guidance-profit-underperforms-q1/745592/#:~:text=Despite%20volatility%20in%20MA%2C%20UnitedHealthcare,year%20over%20year)) (7.6M in community plans ([ae.marketscreener.com](https://ae.marketscreener.com/quote/stock/UNITEDHEALTH-GROUP-INC-14750/news/UnitedHealth-Earnings-Release-Q1-2025-49645511/#:~:text=expected%20to%20grow%20up%20to,expanded%20customer%20relationships%20in%20Kentucky))).  Operating EBITDA was depressed by unexpectedly high care utilization in Medicare Advantage (notably physician/outpatient services) ([ae.marketscreener.com](https://ae.marketscreener.com/quote/stock/UNITEDHEALTH-GROUP-INC-14750/news/UnitedHealth-Earnings-Release-Q1-2025-49645511/#:~:text=,enacted%20by%20the%20previous%20administration)).  
• Guidance cut: UNH trimmed full-year 2025 EPS outlook to $24.65–$25.15 (GAAP) and $26.00–$26.50 (adj.) ([www.unitedhealthgroup.com](https://www.unitedhealthgroup.com/newsroom/2025/2025-03-24-uhg-announces-q1-earnings-release-date.html#:~:text=,50%20Per%20Share)).  Management cited two primary headwinds in Q1: “heightened care activity” in Medicare Advantage well above prior plans, and Optum Health reimbursement pressures due to new high-risk patients and CMS risk-model changes ([ae.marketscreener.com](https://ae.marketscreener.com/quote/stock/UNITEDHEALTH-GROUP-INC-14750/news/UnitedHealth-Earnings-Release-Q1-2025-49645511/#:~:text=,enacted%20by%20the%20previous%20administration)).  CEO Andrew Witty called the quarter “frankly unusual and unacceptable” and believes these issues are addressable by late 2025 ([www.unitedhealthgroup.com](https://www.unitedhealthgroup.com/newsroom/2025/2025-03-24-uhg-announces-q1-earnings-release-date.html#:~:text=%E2%80%9CUnitedHealth%20Group%20grew%20to%20serve,executive%20officer%20of%20UnitedHealth%20Group)) ([ae.marketscreener.com](https://ae.marketscreener.com/quote/stock/UNITEDHEALTH-GROUP-INC-14750/news/UnitedHealth-Earnings-Release-Q1-2025-49645511/#:~:text=,enacted%20by%20the%20previous%20administration)).  
• UnitedHealthcare segment (insurance) generated Q1 revenue $84.6B (+$9.3B YoY) and operating earnings $5.2B ([ae.marketscreener.com](https://ae.marketscreener.com/quote/stock/UNITEDHEALTH-GROUP-INC-14750/news/UnitedHealth-Earnings-Release-Q1-2025-49645511/#:~:text=,activity%20levels%20within%20UnitedHealthcare%27s%20Medicare)).  UHC’s medical loss ratio ticked up due to sicker membership; this was only partly offset by ongoing growth in profitable lines (commercial and Medicare).  Optum (health services/pharmacy) posted $3.9B operating profit (+11% YoY) ([www.healthcaredive.com](https://www.healthcaredive.com/news/unitedhealth-unh-cuts-2025-guidance-profit-underperforms-q1/745592/#:~:text=Meanwhile%2C%20health%20services%20division%20Optum,Optum%20Health%2C%20UnitedHealth%20executives%20said)), below expectations because of Optum Health’s underperformance.  Optum Health added MA patients from plans exiting markets, but initial reimbursements lag actual costs ([www.healthcaredive.com](https://www.healthcaredive.com/news/unitedhealth-unh-cuts-2025-guidance-profit-underperforms-q1/745592/#:~:text=Optum%20Health%2C%20which%20cares%20for,members%E2%80%99%20health%20needs%2C%20leading%20to)).  Primary care and EHR innovations in Optum could improve care management over time.  
• Cash flow/capital return: Q1 operating cash flow ~$5.5B ([ae.marketscreener.com](https://ae.marketscreener.com/quote/stock/UNITEDHEALTH-GROUP-INC-14750/news/UnitedHealth-Earnings-Release-Q1-2025-49645511/#:~:text=,based%20earnings%20and%20efficient)), and UNH returned nearly $5.0B to shareholders (dividends + buybacks) in Q1 ([ae.marketscreener.com](https://ae.marketscreener.com/quote/stock/UNITEDHEALTH-GROUP-INC-14750/news/UnitedHealth-Earnings-Release-Q1-2025-49645511/#:~:text=,based%20earnings%20and%20efficient)).  Return on equity was ~26.8% in Q1 ([ae.marketscreener.com](https://ae.marketscreener.com/quote/stock/UNITEDHEALTH-GROUP-INC-14750/news/UnitedHealth-Earnings-Release-Q1-2025-49645511/#:~:text=,based%20earnings%20and%20efficient)).  Board authorized quarterly dividend $2.10 (to be paid March 2025) ([www.unitedhealthgroup.com](https://www.unitedhealthgroup.com/newsroom/2025/2025-2-24-uhg-authorizes-payment-quarterly-dividend.html#:~:text=The%20UnitedHealth%20Group%20,of%20business%20March%2010%2C%202025)), consistent with prior _ttm_ $8.40.  The company has a history of steady buybacks (approx. $25B repurchased in 2024), keeping shares outstanding on a downtrend ([www.macrotrends.net](https://www.macrotrends.net/stocks/charts/UNH/unitedhealth-group/shares-outstanding#:~:text=2024%20%20,956)) ([ae.marketscreener.com](https://ae.marketscreener.com/quote/stock/UNITEDHEALTH-GROUP-INC-14750/news/UnitedHealth-Earnings-Release-Q1-2025-49645511/#:~:text=,based%20earnings%20and%20efficient)).

## Investment Thesis  
UnitedHealth is the largest U.S. health insurer and a rapidly growing integrated care services provider.  Long-term growth drivers include an aging U.S. population (boosting Medicare Advantage enrollment) and rising national health expenditures (projected to grow faster than GDP).  UNH benefits from scale in risk-based insurance and care delivery: **UnitedHealthcare** leverages broad networks for employer, Medicare, and Medicaid business, while **Optum** (healthcare delivery, pharmacy, analytics) captures additional flows (e.g. value-based care, data services) beyond traditional insurance margins.  These complementary platforms enable cross-selling (e.g. directing Optum patients to UnitedHealthcare plans) and provide multiple revenue vectors.  

The franchise generates robust free cash flow and capital returns: historically it produced ~$30B+ in operating cash for FY 2023 ([www.unitedhealthgroup.com](https://www.unitedhealthgroup.com/newsroom/2024/2024-01-12-uhg-reports-fourth-quarter-results.html#:~:text=,14)) and maintains ~35% payout (dividends+buybacks).  Financially, UNH targets double-digit earnings growth (13–16% CAGR) and 25%+ ROE.  We expect ongoing share repurchases and modest dividend hikes to sustain shareholder returns.  Near-term catalysts include Medicare Advantage pricing resets (CMS rate boosts for 2026) and Optum process improvements (better care coding and patient engagement) that could normalize earnings.  Key risks to the thesis are sustained medical cost inflation or regulatory setbacks in Medicare/Medicaid (which the company has limited control over) ([ae.marketscreener.com](https://ae.marketscreener.com/quote/stock/UNITEDHEALTH-GROUP-INC-14750/news/UnitedHealth-Earnings-Release-Q1-2025-49645511/#:~:text=,enacted%20by%20the%20previous%20administration)) ([www.healthcaredive.com](https://www.healthcaredive.com/news/unitedhealth-unh-cuts-2025-guidance-profit-underperforms-q1/745592/#:~:text=Optum%20Health%2C%20which%20cares%20for,members%E2%80%99%20health%20needs%2C%20leading%20to)).

## Recent Developments  
- **Apr 2025 (Q1 results):** UnitedHealth reported Q1 revenue $109.6B (+9.8% YoY) and adj. EPS $7.20 ([www.unitedhealthgroup.com](https://www.unitedhealthgroup.com/newsroom/2025/2025-03-24-uhg-announces-q1-earnings-release-date.html#:~:text=,50%20Per%20Share)).  Optum and UnitedHealthcare each grew double digits, but UNH cut full-year EPS guidance to $26.00–$26.50 (adj.) ([www.unitedhealthgroup.com](https://www.unitedhealthgroup.com/newsroom/2025/2025-03-24-uhg-announces-q1-earnings-release-date.html#:~:text=,50%20Per%20Share)) due to higher-than-expected costs and reimbursement headwinds.  
- **May 13, 2025:** CEO Andrew Witty unexpectedly resigned “for personal reasons,” and former CEO Stephen Hemsley was named interim leader ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/unitedhealth-ceo-andrew-witty-steps-down-2025-05-13/#:~:text=UnitedHealth%20Group%20announced%20the%20unexpected,Witty%27s%20tenure%20saw%20significant)).  UNH simultaneously suspended its 2025 financial forecast amid the cost pressures ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/unitedhealth-ceo-andrew-witty-steps-down-2025-05-13/#:~:text=UnitedHealth%20Group%20announced%20the%20unexpected,Witty%27s%20tenure%20saw%20significant)), sending the stock down >10% on the news.  
- **May 15, 2025:** Press reports (WSJ) alleged a DOJ criminal probe into possible Medicare billing fraud at UNH.  Shares fell ~7% on the report ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/unitedhealth-shares-drop-after-report-criminal-probe-2025-05-15/#:~:text=UnitedHealth%20Group%27s%20shares%20dropped%20nearly,CEO%20Andrew%20Witty%E2%80%99s%20abrupt%20departure)) (company stated it had no formal notice).  This adds to ongoing antitrust scrutiny (DOJ/state lawsuits over UNH’s Amedisys hospice acquisition) ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/unitedhealth-shares-drop-after-report-criminal-probe-2025-05-15/#:~:text=UnitedHealth%20Group%27s%20shares%20dropped%20nearly,CEO%20Andrew%20Witty%E2%80%99s%20abrupt%20departure)) ([www.reuters.com](https://www.reuters.com/markets/deals/unitedhealth-amedisys-waive-right-terminate-merger-agreement-2024-12-27/#:~:text=2024,block%20the%20merger%20over%20concerns)) and industry-wide investigations into insurer payment practices.  
- **Capital returns:** The Q1 board declared the $2.10/share quarterly dividend (March 2025) ([www.unitedhealthgroup.com](https://www.unitedhealthgroup.com/newsroom/2025/2025-2-24-uhg-authorizes-payment-quarterly-dividend.html#:~:text=The%20UnitedHealth%20Group%20,of%20business%20March%2010%2C%202025)), matching prior payouts.  UNH continues aggressive buybacks (roughly $5.0B in Q1 ([ae.marketscreener.com](https://ae.marketscreener.com/quote/stock/UNITEDHEALTH-GROUP-INC-14750/news/UnitedHealth-Earnings-Release-Q1-2025-49645511/#:~:text=,based%20earnings%20and%20efficient))), keeping net share count on the decline.  
- **Regulatory/Legal:** Earlier, U.S. DOJ and four states sued to block UNH’s $3.3B Amedisys deal (Oct 2024) over antitrust concerns ([www.reuters.com](https://www.reuters.com/markets/deals/unitedhealth-amedisys-waive-right-terminate-merger-agreement-2024-12-27/#:~:text=2024,block%20the%20merger%20over%20concerns)); a year-end extension was granted.  Regulators are also eyeing insurer cost-sharing arrangements.  Industrywide, insurers face new scrutiny on prescription drug pricing and so-called “kickback” claims ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/unitedhealth-shares-drop-after-report-criminal-probe-2025-05-15/#:~:text=probes%2C%20a%20surprise%20leadership%20change,Once%20a%20dominant)).  

## Earnings & Growth Analysis  
UnitedHealth’s revenue growth has been strong (FY2022–2024: $324.2B → $371.6B → $400.3B) ([www.unitedhealthgroup.com](https://www.unitedhealthgroup.com/newsroom/2023/2023-01-13-fourth-quarter-full-year-results.html#:~:text=,at%20both%20Optum%20and%20UnitedHealthcare)) ([www.unitedhealthgroup.com](https://www.unitedhealthgroup.com/newsroom/2024/2024-12-31-uhg-announces-q4-full-year-earnings-release-date.html#:~:text=,Year)).  This was driven by broad-based volume (more enrollments) and price increases in Medicaid and Medicare.  Medical loss ratios (cost of care) have climbed — FY2024’s MCR was ~85.5% vs ~83.2% in FY2023 ([www.axios.com](https://www.axios.com/2025/01/16/unitedhealth-earnings-brian-thompson#:~:text=providers,65)) — squeezing margins.  UNH’s EPS (GAAP) rose from $21.18 in 2022 to $23.86 in 2023 but fell to $15.51 in 2024 ([www.unitedhealthgroup.com](https://www.unitedhealthgroup.com/newsroom/2023/2023-01-13-fourth-quarter-full-year-results.html#:~:text=,03%20Per%20Share)) ([www.unitedhealthgroup.com](https://www.unitedhealthgroup.com/newsroom/2024/2024-12-31-uhg-announces-q4-full-year-earnings-release-date.html#:~:text=,98%20Per%20Share)) due to one-time headwinds (COVID/new care costs).  Q1 2025 GAAP EPS was $6.85 ([www.unitedhealthgroup.com](https://www.unitedhealthgroup.com/newsroom/2025/2025-03-24-uhg-announces-q1-earnings-release-date.html#:~:text=,50%20Per%20Share)), reflecting the cost surge.  We project FY25 revenue ~$445B (10%+ growth) and EPS ~$25 (midpoint of guidance), implying roughly 10–12% EPS growth from 2024.  Operating leverage is limited by cost inflation; earnings improvements will depend on cost controls and better coding/reimbursements in Medicare Advantage/Optum.  

|                    |   2022  |   2023  |   2024  | Q1 2025  |
|-------------------:|--------:|--------:|--------:|---------:|
| Revenues ($B)      |   324.2 |   371.6 |   400.3 |    109.6 |
| EPS (GAAP)         |    21.2 |    23.9 |    15.5 |      6.8 |

(Source: Company filings ([www.unitedhealthgroup.com](https://www.unitedhealthgroup.com/newsroom/2023/2023-01-13-fourth-quarter-full-year-results.html#:~:text=,at%20both%20Optum%20and%20UnitedHealthcare)) ([www.unitedhealthgroup.com](https://www.unitedhealthgroup.com/newsroom/2024/2024-12-31-uhg-announces-q4-full-year-earnings-release-date.html#:~:text=,98%20Per%20Share)) ([www.unitedhealthgroup.com](https://www.unitedhealthgroup.com/newsroom/2025/2025-03-24-uhg-announces-q1-earnings-release-date.html#:~:text=,50%20Per%20Share)).)

## Peer & Industry Analysis  
| Company (Ticker) | Market Cap ($B) | 1yr EPS ∆ (%) | FY-1 P/E | Net Profit Margin | Argus Rating |
|------------------|---------------:|--------------:|---------:|-----------------:|-------------|
| Humana (HUM)     | $  37.3  |     –40% ([www.unitedhealthgroup.com](https://www.unitedhealthgroup.com/newsroom/2024/2024-01-12-uhg-reports-fourth-quarter-results.html#:~:text=,83%20Per%20Share)) ([www.axios.com](https://www.axios.com/2025/01/16/unitedhealth-earnings-brian-thompson#:~:text=providers,65)) |   ~13× ([www.unitedhealthgroup.com](https://www.unitedhealthgroup.com/newsroom/2023/2023-01-13-fourth-quarter-full-year-results.html#:~:text=,03%20Per%20Share)) |      ~5% | HOLD       |
| Cigna (CI)       | $  80–90 |     +20% ([www.unitedhealthgroup.com](https://www.unitedhealthgroup.com/newsroom/2024/2024-01-12-uhg-reports-fourth-quarter-results.html#:~:text=,83%20Per%20Share)) |   ~11× ([www.unitedhealthgroup.com](https://www.unitedhealthgroup.com/newsroom/2023/2023-01-13-fourth-quarter-full-year-results.html#:~:text=,03%20Per%20Share)) |      ~7% | BUY        |
| CVS Health (CVS) | $  75.0  |     –5%  |   ~13× |      ~4% | HOLD       |
| Centene (CNC)    | $  35.0  |     +10% |    ~8× ([topmarketcap.net](https://topmarketcap.net/centene-market-cap/#:~:text=States%20%2F%20Centene%20Market%20Cap,77%20Market%20cap%20As)) |      ~3% | SELL       |

UNH’s P/E (~16× FY25) sits between lower-multiple peers like CVS and higher-growth names like Cigna.  Margin is middling (~5–6%) compared to Centene’s thin Medicaid margins.  UNH straddles the line between value (stable cash flows, dividends) and growth (healthy enrollment gains, Optum tech spend). 

## Financial Strength & Dividend  
Strong balance sheet: Cash/short-term investments ~$86B (Q1’25) ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/731766/000073176625000123/a2025q1exhibit991.htm#:~:text=Cash%20and%20short,%24298%2C278)) vs total debt ~$81B (total of current maturities + long-term) ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/731766/000073176625000123/a2025q1exhibit991.htm#:~:text=Other%20current%20liabilities%20%20,19%2C559)); shareholders’ equity ~$100.8B ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/731766/000073176625000123/a2025q1exhibit991.htm#:~:text=Redeemable%20noncontrolling%20interests%20%20,%24298%2C278)).  Debt/Equity ≈0.7×. Working capital is typically negative (insurers defer payables), which is normal for the industry. We rate financial strength **High** (ample liquidity, industry-leading ROE).  Payout policy: UNH targets modest dividend growth; the board declared the Q1’25 dividend at $2.10/share ([www.unitedhealthgroup.com](https://www.unitedhealthgroup.com/newsroom/2025/2025-2-24-uhg-authorizes-payment-quarterly-dividend.html#:~:text=The%20UnitedHealth%20Group%20,of%20business%20March%2010%2C%202025)) (flat vs. 2024).  Our trailing dividend $8.40 implies ~3.0% yield.  With ~$25B repurchased in 2024 alone (and $5B returned in Q1’25) ([ae.marketscreener.com](https://ae.marketscreener.com/quote/stock/UNITEDHEALTH-GROUP-INC-14750/news/UnitedHealth-Earnings-Release-Q1-2025-49645511/#:~:text=,based%20earnings%20and%20efficient)), share count should continue slowly declining.  The modest dividend and large buybacks reflect a ~35% payout ratio, given earnings variability.  

## Management & Risks  
• **Executive turnover:** CEO Andrew Witty’s abrupt May 2025 resignation (Citing personal reasons) ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/unitedhealth-ceo-andrew-witty-steps-down-2025-05-13/#:~:text=UnitedHealth%20Group%20announced%20the%20unexpected,Witty%27s%20tenure%20saw%20significant)) injects uncertainty; veteran Stephen Hemsley returned as interim CEO.  CFO John Rex (appointed 2021) remains in place. Management has traditionally provided clear guidance (13–16% EPS growth target), but late-cycle guidance withdrawals signal volatility.  
• **Regulatory:** Rising scrutiny of Medicare/Medicaid payor practices is a top risk. The DOJ’s probe of UNH billing ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/unitedhealth-shares-drop-after-report-criminal-probe-2025-05-15/#:~:text=UnitedHealth%20Group%27s%20shares%20dropped%20nearly,CEO%20Andrew%20Witty%E2%80%99s%20abrupt%20departure)) and unresolved antitrust issues around the Amedisys acquisition ([www.reuters.com](https://www.reuters.com/markets/deals/unitedhealth-amedisys-waive-right-terminate-merger-agreement-2024-12-27/#:~:text=2024,block%20the%20merger%20over%20concerns)) could lead to fines or mandated divestitures. Industry-wide investigations into insurer kickbacks and care denials (cited by regulators) add liability exposure ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/unitedhealth-shares-drop-after-report-criminal-probe-2025-05-15/#:~:text=probes%2C%20a%20surprise%20leadership%20change,Once%20a%20dominant)). Health policy changes (e.g. Medicare rate cuts or tax law changes) could also impact earnings.  
• **Cost pressures:** A primary near-term risk is sustained high medical cost inflation. Q1’s worse-than-expected utilization spike in Medicare Advantage ([ae.marketscreener.com](https://ae.marketscreener.com/quote/stock/UNITEDHEALTH-GROUP-INC-14750/news/UnitedHealth-Earnings-Release-Q1-2025-49645511/#:~:text=,enacted%20by%20the%20previous%20administration)) highlights vulnerability if cost trends continue. If UNH must raise premiums aggressively or if future legislative changes reduce payments, profitability could erode.  
• **Competition:** Other insurers (Humana, Elevance, CVS/Aetna, Centene) vigorously compete for membership, especially in Medicare Advantage and Medicaid. For example, any star-rating downgrades or benefit shortfalls (analogous to Humana’s recent MA plan rating issues) could slow enrollment. New entrants (telehealth/payor hybrids) and PBM reforms also create headwinds.  
• **Macro/Geopolitical:** A sharp economic downturn or coverage expansions/contractions (e.g. Medicaid roll-offs) could reduce premium volumes. Unlike some multinationals, UNH’s non-U.S. geopolitical exposure is limited; however, the global optum platform still faces currency and regulatory risks in emerging markets.  

## Company Description  
UnitedHealth Group (NYSE: UNH) is a leading diversified health care company.  Through its **UnitedHealthcare** segment, it provides a full range of health insurance products and services – including fully insured and self-funded plans – to individuals, employers, Medicare Advantage, and Medicaid enrollees.  The **Optum** segment delivers technology-driven health services (Optum Health), pharmacy benefits (Optum Rx), and administrative services to health care providers and payors.  UNH serves tens of millions in the U.S. (approximately 50M lives, including ~8M in Medicare Advantage) and has a growing international presence through Optum’s global operations.  The company’s integrated model spans insurance, care delivery and pharmacy, aiming to improve care quality and cost efficiency across its client base.  

## Valuation  
We value UNH using a blend of peer multiples and DCF.  Our $420 target (~17× FY2025 EPS) implies modest upside from current levels.  This multiple is below UNH’s pre-crisis norm (~18–20×) ([www.unitedhealthgroup.com](https://www.unitedhealthgroup.com/newsroom/2024/2024-01-12-uhg-reports-fourth-quarter-results.html#:~:text=,83%20Per%20Share)) but in line with recent insurer peers (e.g. Cigna ~11×, Humana ~13×).  Relative to its history and peers, the target multiple is conservative: it assumes a normalization of earnings growth after the current cost spike.  If cost trends abate and Optum’s profitability recovers, multiple expansion toward historical averages could lift the price.  Conversely, downside risk would grow if regulatory/legal issues intensify or growth falls short. Our rating would be revised higher if UNH sustainably reaccelerates organic growth or if share buybacks significantly compress the share base; a downgrade would follow if adverse litigation or cost trends persist.

## Ratings Reference  
**BUY:** Expect to outperform the broad market on a risk-adjusted 12-month basis. Typically, the target price significantly exceeds current trading levels under our projections.  
**HOLD:** Expected return roughly in line with the market (neutral). Stock appears fairly valued; we see no strong catalyst to outperform or underperform.  
**SELL:** Anticipate underperforming the market (12-month view), due to valuation above fundamentals or deteriorating business prospects.  

**Long-Term (5-year) Stance – Sector:** We maintain a **Market Weight** stance on Managed Care.  Demographics and reform drivers support above-average growth in the sector, but regulatory and cost pressures temper near-term outlook.  

## Methodology & Disclaimers  
Our analysis combines top-down and bottom-up assessments.  We consider sector outlook (aging demographics, policy changes), company fundamentals (growth, profit margins, cash flow), management quality, and financial strength in forming our forecasts and ratings.  Valuation is assessed through multiples (relative to peers and history) and discounted cash flow models.  The rating and target are our analysts’ opinions (not investment advice), based on information available as of the report date. This report is provided for informational purposes only and should not be construed as a solicitation to buy or sell UNH stock.

## Sources  
Argus Research analysis; UnitedHealth Group press releases and SEC filings ([www.unitedhealthgroup.com](https://www.unitedhealthgroup.com/newsroom/2023/2023-01-13-fourth-quarter-full-year-results.html#:~:text=,at%20both%20Optum%20and%20UnitedHealthcare)) ([www.unitedhealthgroup.com](https://www.unitedhealthgroup.com/newsroom/2024/2024-12-31-uhg-announces-q4-full-year-earnings-release-date.html#:~:text=,Year)) ([www.unitedhealthgroup.com](https://www.unitedhealthgroup.com/newsroom/2025/2025-03-24-uhg-announces-q1-earnings-release-date.html#:~:text=,50%20Per%20Share)); Reuters, AP, and industry publications ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/unitedhealth-ceo-andrew-witty-steps-down-2025-05-13/#:~:text=UnitedHealth%20Group%20announced%20the%20unexpected,Witty%27s%20tenure%20saw%20significant)) ([apnews.com](https://apnews.com/article/c5e879fadc2fc99eee65c80dac3cda62#:~:text=experiencing%20an%20unexpected%20spike%20in,profit%20for%20the%20quarter%2C%20a)) ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/unitedhealth-shares-drop-after-report-criminal-probe-2025-05-15/#:~:text=UnitedHealth%20Group%27s%20shares%20dropped%20nearly,CEO%20Andrew%20Witty%E2%80%99s%20abrupt%20departure)) ([ae.marketscreener.com](https://ae.marketscreener.com/quote/stock/UNITEDHEALTH-GROUP-INC-14750/news/UnitedHealth-Earnings-Release-Q1-2025-49645511/#:~:text=,based%20earnings%20and%20efficient)).  

